Erythropoietin and Erythropoiesis in Anemic Man
|
|
- Tyrone Marsh
- 5 years ago
- Views:
Transcription
1 From by guest on January 22, 219. For personal use only. Erythropoietin and Erythropoiesis in Anemic Man Following Androgens By RAYMOND ALEXANIAN T hat androgenic hormones stimulate erythropoiesis in animals and man has been known for many years.1 2 The principle mechanism for this activity probably results from an increased production of erythropoietin since both serum and urine levels are elevated by androgens.35 Even when plasma erythropoietin content is high, as in most anemias, further enhancement may occur after administration of testosterone.#{176} In man, the relationship between androgen dose and erythropoietin response has not been clarified, and the degree of erythropoietin stimulation in anemic patients has not been compared with the effect in normal man. These problems were studied in order to define a more rational basis for the use of androgens in the treatment of patients with anemia due to bone marrow failure. This report correlates the urinary excretion of erythropoietin with changes in red cell volume in normal, hypogonadal, and anemic patients after different doses of androgenic hormones. Results suggested that further stimulation of erythropoietin production by a synergistic effect between androgens and anemia accounts for the increased erythropoiesis produced in some anemic patients by large doses of androgens. MATERIAL AND METHOD Urinary erythropoietin excretion was measured serially during androgenic hormone therapy of 26 patients ranging in age from 3 to 78 years. Red cell indices were normal bone marrow hemosiderin was present, and creatinine clearance exceeded 7 ml./min. in all subjects. erum iron and transferrin concentrations were determined by the method of Ramsay.7 Transaminase levels were normal before therapy, and were measured serially after institution of androgens. No red cell transfusions were given during the study period. When required for underlying malignant disease (3 patients), the nature, dose, or schedule of daily maintenance chemotherapy was not altered. Red cell volume was measured using the 51Cr technic8 at least 3 months after institution of androgens; control measurements were made at beast 2 months after cessation of therapy. Results were expressed in mb/rn.2, and compared with ranges derived in this laboratory for normal men and women. The urinary excretion of erythropoietin was assessed in polycythemic mice, and expressed in tandard B units/day, as described previously.5 All subjects were divided, according to their hematobogic and endocrine status, into 3 treatment groups. ix males constituted the control group. Ages ranged from 43 to 61 years. All had indolent malignancies in complete remission that did not require any therapy during the study period. Diagnoses included nodular lymphoma (3 patients), localized Front the Department of Medicine, The University of Texas M.D. Anderson Hospital and Tumor Institute at Houston, Texas This work was supported by U..P.H.. Grant AM First submitted August 9, 1968; accepted for publication November 4, RAYMOND ALEXANIAN, M.D.: Associate Professor of Medicine, The University of Texas M. D. Anderson Hospital and Tumor lnstitute. 564 BLOOD, VOL. 33, No. 4 (APRIL), 1969
2 From by guest on January 22, 219. For personal use only. ERYTHIIOPOIETIN AND ERYTHROPOIEI 565 Hodgkin s disease ( 2 patients ), and localized reticulum cell sarcoma ( 1 patient). Bone marrow cellularity on clot section was normal; erythropoiesis was considered normal on the basis of normal hematocrit ( 42 to 48 volumes percent ), normal red cell volume ( 16 to 122 mb/rn.2 ), and normal erythropoietin excretion (.7 to 2.2 t. B units/day). Eight males were hypogonadal with decreased testosterone production rate ( < 2 mg./ day) and/or 17-ketosteroid excretion ( <3 mg./day). Hypophysectomy for pituitary adenoma had been performed on all at least 6 months previously. Replacement therapy with thyroid and prednisone was continued during the study period. With one exception basal hematocrit was less than 41 volumes per cent ( median 39 ), and red cell volume was bess than 16 ml./m.2 ( median 95 ). In all, control erythropoietin excretion was less than.8 units/day. ix males and 6 females formed the group with anemia due to bone marrow failure. Diagnoses included advanced Hodgkin s disease (4 patients), multiple myeboma (4 patients), lymphosarcoma (2 patients), and rnyelofibrosis ( 2 patients). Impairment of marrow function from prior, barge- or multiple-field radiotherapy was the major factor contributing to anemia in 8 subjects. Marrow infiltration by malignant cells was considered the major cause of anemia in 4 patients. Hematocrits ranged from 29 to 4 volumes per cent ( median 36 ), and red cell volume ranged from 64 to 79 per cent of the normal mean value for each sex. Basal erythropoietin excretion was either elevated ( 7 patients ), or at the upper limit of the normal range for each sex ( 5 patients ). Fbuoxymesterone#{176} was given to all patients for at least 3 months. The daily oral dose was 1 rn/meter2 for hypogonadal males and anemic females, and 4 mg/meter2 for control and anemic males. REULT Following androgenic treatment, all subjects demonstrated an increase in urinary erythropoietin; two thirds of the patients studied developed an elevation in red cell volume of at least 15 per cent. The kinetics of the erythropoietin response differed in each treatment group. Control Males In males forming the control group, median erythropoietin excretion increased eightfold from 1. to 8.5 t. B units/day after one month of fluoxymesterone treatment (Fig. 1). This level was greater (p <.1) than previously induced in normal men by lower doses of androgen.5 ubsequent values were less, decreasing to a median of 2.3 units/day by the third month. At this time, the median increase was 5 volumes per cent (range 1 to 8) in hematocrit and 15 per cent (range 7 to 25 percent) in red cell volume (Fig. 2). There was no correlation between the maximum level of erythropoietin excretion and the degree of subsequent erythrocytosis. Within one week after ceasing androgenic therapy, erythropoietin excretion fell to or below the control range (Fig. 1). Hypogonadal Males Basal erythropoietin excretion in hypogonadal males ranged from.3 to.7 t. B units/day, values less than found previously in normal men.5 After one month of androgen therapy, all patients showed erythropoietin stimulation of 2 to 8 times control, with a median maximum excretion of 1.9 units/ day (range 1. to 4.8) (Fig. 3). This level was not different (p.4) from values #{176}Upjohn Company, Kalamazoo, Michigan.
3 From by guest on January 22, 219. For personal use only. 566 ALEXANIAN jD - I. 5 2 I I DURATION OF TREATMENT IN WEEK Cessotion of Fluoxymesterone Fig. 1.-Erythropoietin excretion in control men during fluoxymesterone therapy in a daily dose of 4 mg./m.2. The shaded area includes 85 per cent of all values. 4 #{149} tj.moies : Femoles C : Control #{149} timuloted #{149} #{149} a. a I-I 2 8 Li (5 z z 2 #{149} #{149} : ; Fig. 2.-Red cell volume before and after fluoxymesterone in control and hypogonadal men, and in patients anemic from marrow failure. The shaded areas indicate the normal range for each sex I 8 NORMAL HYPOGONADAL ANEMIC
4 From by guest on January 22, 219. For personal use only. ERYTHROPOIETIN AND ERYTHROPOIEI 567 found previously in normal men, but was less ( p <.1 ) than found in normal women after similar doses of androgen.5 The maximum level in hypogonadal males was less than that measured in the control group of males after larger doses ( p <.1 ) ( Fig. 1 ). In hypogonadal males, median hematocrit increased from 39 ( range 38 to 45 ) to 53 ( range 44 to 58 ) volumes per cent, and red cell volume increased by 26 per cent ( range 18 to 54 per cent) ( Fig. 2 ). In all but one patient, the red cell volume reached normal or polycythemic levels. The exception was the most anemic subject who required treatment with Dilantin and had megaloblastic changes in the bone marrow. One week after cessation of androgens, urinary erythropoietin returned to the control value or less ( Fig. 3 ). When the response in individual patients was compared, there was no correlation between the degrees to which erythropoietin and red cell mass were stimulated. Males and Females Anemic from Marrow Failure Twelve anemic patients received fluoxymesterone; 6 women received a daily dose of 1 mg./m.2 and 6 men received 4 mg./m.2. Control levels of erythropoietin excretion ranged from.9 to 3.5 units in women and 1.2 to 1 units in men. The median level for all patients was 2.1 units/day. After one month of therapy, erythropoietin excretion increased in all at least fivefold to more than 1 units/day to a median maximum excretion of 33 units/day ( Fig. 4). This level was significantly greater than found previously in normal men and women after similar doses of androgen ( Fig. 1 ). ubsequent values were less, with a median excretion of 1 units/ day after 3 months. Termination of therapy was followed by return to the control range or less, but not to the undetectable levels occasionally found in normal and hypogonadal males. Red cell volume increased at least 15 per cent in 3 of 7 anemic patients studied ( Fig. 2 ) ; one patient s red cell volume increased to the normal range. One additional patient, in whom no blood volume studies were done, increased his hematocrit 7 volumes per cent. Thus, at least one third of the anemic patients in this series developed some erythropoietic response subsequent to an enhanced erythropoietin excretion. There was no correlation between basal or maximum erythropoietin levels and the subsequent elevation in red cell volume, an observation consistent with the variable degrees of anemia and bone marrow reserve present in these patients. Miscellaneous Effects No change was found in reticubocyte concentration, white blood cell count, or platelet count. Mild anabolic effects, with improved appetite and weight, occurred in most subjects. Transferrin saturation fell from a median percentage of 29 (range 16 to 46) to 18 (range 12 to 25) in 14 normal and hypogonadal males after 1 or 2 months of fluoxymesterone treatment. Marked elevations of transferrin concentration accounted for most of this change. In one hypogonadal male, serum transferrin level increased from 34 to 61 jig. per cent. Fluoxymesterone was well tolerated in more than 9 per cent of subjects. light dose reductions were required for two women, in one because of hirsutism and in the other because of irritability. Many patients experienced
5 From by guest on January 22, 219. For personal use only. 568 ALEXANIAN C , 21- I,, 2 ) t Cessation Fluoxymesterone of 1,1 II II DURATION OF TREATMENT IN WEEK Fig. 3.-Erythropoietin excretion in hypogonadab males during fluoxymesterone therapy in a daily dose of 1 mg./m.2. The shaded area includes 85 per cent of all values. occasional, but mild, leg cramps. No patient developed jaundice. Transaminase levels exceeded 5 mg. per cent on more than one measurement in 2 per cent of males receiving large doses of fluoxymesterone ( i.e., 4 mg./meter/day), but cessation of therapy was required in only one. This patient developed nausea and weakness associated with an GOT content of 29 mg. per cent and an GPT level of 62 mg. per cent, changes which returned to normal within 2 weeks after therapy was terminated. DIsCuIoN Erythropoietin production was evaluated by assessing changes in the urinary excretion of erythropoietin. The renal clearance of erythropoietin is low,9 and androgens may influence erythropoietin excretion by a direct effect on renal blood flow.1 Thus, only marked changes in erythropoietin excretion (i.e., > 3 X control) in groups of patients were considered in this evaluation of erythropoietin production. With less variability in erythropoietin excretion and when individual patients are compared, renal and other factors are more likely to obscure significant differences in erythropoietin production. This may explain our failure to detect any correlation between the degrees to which erythropoietin and red cell mass were stimulated among the patients in the control and hypogonadal treatment groups. Plasma was not used because of the difficulty in demonstrating erythropoietin in normal plasma, or in anemic plasma when the urinary excretion was less than 1 t. B units/day.12 Previous studies ruled out an indirect stimulation of endogenous erythropoiesis in assay animals by fluoxymesterone or its metabolites.5 Neutralization by an antihuman erythropoietin antibody confirmed the identity of the stimulating sub-
6 From by guest on January 22, 219. For personal use only. ERYTHROPOIETIN AND ERYTHROPOIEI s - uj:. : t Cessation Fluoxymesterone of I I I DURATION OF TREATMENT IN WEEK Fig. 4.-Erythropoietin excretion in 12 anemic men and women during fluoxymesterone therapy. The shaded area includes 85 per cent of all values. stance in urine concentrates with human erythropoietin.5 In view of the slow and small increment in erythropoiesis induced by androgens,2 changes in red cell volume were used to assess an effective marrow response after at least 3 months of therapy. Fluoxymesterone was given because of the convenience of oral administration, the established capacity to stimulate red cell production in man,13 and the desire to avoid the serious hepatic toxicity reported with other anabolic agents. 4 Using lower doses, masculinizing side effects in women were infrequent and minimal in degree. With the larger doses given to men, hepatic toxicity was uncommon, mild, and reversible. ince marrow iron stores were adequate, the observed decrease in per cent saturation of transferrin was attributed to an effect of androgens on transferrin metabolism in a manner unrelated to a change in erythropoiesis. The close relationship between androgenic hormones and erythropoiesis has been known for many years. The anemia following orchidectomy is corrected by testosterone. Large doses of androgenic hormones induce an erythrocytosis in certain animals and human beings, 2 an effect preceded by increased levels of erythropoietin.36 Erythropoietin antibodies suppress the enhancement of erythropoiesis induced by testosterone.15 Gordon has demonstrated that andro-
7 From by guest on January 22, 219. For personal use only. 57 ALEXANIAN gens augment the production of a renal factor which reacts with a serum component in order to elaborate active erythropoietin. 6 These observations support the conclusion that the marrow stimulation induced by androgens results primarily from an increased production of erythropoietin. Whether androgens also exert a direct effect on the bone marrow independent of erythropoietin was not evaluated in this study. The detection of erythropoietin in the urine of normal human beings 17,18 and its suppression by increased numbers of circulating red blood cells19 indicates that steady-state erythropoiesis in normal man results from continuous erythropoietin production and activity. The higher level of erythropoiesis and erythropoietin excretion in adult men, in contrast to women and prepubertal boys, 7 18 presumably results from a higher level of androgenic hormone stimulation. This explanation is supported by the subnormal erythropoietin excretion and red cell volume found in hypogonadal men, with restitution to normal and elevated levels by androgen replacement. This effect in subjects hypophysectomized for pituitary tumors indicates that the erythropoietin-stimulating capacity of androgens is not mediated or dependent upon those pituitary hormones with similar erythropoietic activity, such as growth hormone and vasopressin.2#{176} 21 Thus, the mild anemia usually found in hypogonadal males may be attril)uted primarily to decreased erythropoietin production. The greater erythropoietin response found in normal women,5 in comparison with the effect in hypogonadal males after similar androgen doses, is consistent with observations by Jepson that other endocrine factors may also influence erythropoietin production.2-2 Less erythropoietin stimulation developed in normal males than in normal females after a standardized dose of androgen.5 22 Normal men required about four times larger doses of androgen to achieve a level of erythropoietin excretion comparable to that induced in normal women. A similar sex difference and dose-response relationship has been observed in mice.23 Thus, maximum tolerated doses of androgenic hormones are justified in male patients when mdicated in the treatment of certain anemias due to bone marrow failure.24 ignificant elevation in red cell volume was induced by androgens in several patients with mild anemia caused by impaired marrow function. Despite erythropoietin values higher than those induced in normal or hypogonadal males, the frequency and degree of red cell stimulation in these anemic patients was less. imilar to observations by others,6 25 these studies suggest that further enhancement of a previously elevated rate of erythropoietin production accounts to a major degree for the increased erythropoiesis that occurs in some anemic patients receiving androgen treatment. The marked degree of erythropoietin elevation in anemic patients, to levels higher than those predicted from the response in normal man, suggests that androgens and anemia are synergistic in their stimulation of erythropoietmn production. imilar synergism between androgens and hypoxia has been demonstrated in animals.3 4 Thus, enhancement of erythropoietin production to maximum levels may provide a better opportunity for significant marrow response in some patients with anemia resulting from marrow failure.
8 From by guest on January 22, 219. For personal use only. ERYTHROPOIETIN AND ERYTHROPOIEI 571 CONCLUION Erythropoietin excretion was correlated with red cell volume during androgenic hormone therapy of selected patients with normal and decreased crythropoiesis. Normal men required larger doses of androgen to achieve the same degree of erythropoietin stimulation as that previously induced in women with lower doses. In hypogonadal males, low erythropoietin excretion was enhanced, and subnormal red cell volume reached normal or polycythemic levels. Thus, mild anemia in hypogonadal males probably results from decreased erythropoietin production. In patients with anemia due to marrow failure, previously elevated levels of urinary erythropoietin increased markedly within one month to at least 1 X normal. The degree of erythropoietin enhancement conformed with a stimulation of erythropoietin production by a synergistic effect from androgens and anemia. Results suggested that further elevation of erythropoietin production accounts to a major degree for the increased erythropoiesis that occurs in some anemic patients with large doses of androgenic hormones. ACKNOWLEDGMENT The author is indebted to Dr. V. W. Cole, Dr. C. C. hullenberger, and Dr. J. F. Gamble for contributing patients to this study and to Brenda Doherty for bler technical assistance. REFERENCE 1. teinglass, P., Gordon, A.., and Charipper, H. A. : Effect of castration and sex hormones on the blood of rats. Proc. oc. Exp. Biob. Med. 48:169, Kennedy, B. J., and Gilbertson, A..: Increased erythropoiesis induced by androgenie-hormone therapy. New Eng. J. Med. 256:719, Mirand, E. A., Gordon, A.., and Wenig, J.: Mechanism of testosterone action in erythropoiesis. Nature 26:27, Fried, W., and Gurney, C. W.: Erythropoietin effect of plasma from mice receiving testosterone. Nature 26:116, Abexanian, R., Vaughn, W. K., and Ruchebman, M. W.: Erythropoietin excretion in man following androgens. J. Lab. Clin. Med. 7:777, Rishpon-Meyerstein, N., Kilbridge, T., imone, J., and Fried, W.: The effect of testosterone on erythropoietin levels in anemic patients. Blood 31:453, Ramsay, W. N. M.: The determination of iron in blood plasma or serum. Clin. Chim. Acta 2:221, Donohue, D. M., Motubsky, A. G., Giblett, E. R., Pirzio-Biroli, G., Viramatti, V., and Finch, C. A.: Cr5 as a red cell tag. Brit. J. Haemat. 1:249, Weintraub, A. H., Gordon, A.., Becker, E. L., Camiscoli, J. R., and Contrera, J. F. : Plasma and renal clearance of exogenous erythropoietin in the dog. Amer. J. Phys. 27:523, Dontas, A.., Papanicolaou, N. T., Papanayiotou, P., and Mabamos, B. K.: Long-term effects of anabobic steroids on renal functions in the aged subject. J. Ceront. 22:268, Mirand, E. A., Weintraub, A. H., Gordon, A.., Prentice, T. C., and Grace, J. T., Jr.: Erythropoietin activity of untreated and deproteinized normal human plasma. Proc. oc. Exp. Biol. Med. 118:823, Abexanian, R.: Unpublished observations. 13. Kennedy, B. J.: Fluoxymesterone in the treatment of advanced breast cancer. Cancer 1:813, anchez-medal, L., Gomez-Leal, A., and Duarte-Zapata, L.: Anabolic therapy in aplastic anemia. Blood 28:979, 1966 (Abstract). 15. choobey, J. C.: Inhibition of erythropoietin stimulation by testosterone in polycythemic mice receiving anti-erythropoietin. Proc. oc. Exp. Biol. Med. 122:42, 1966.
9 From by guest on January 22, 219. For personal use only. 572 ALEXANIAN 16. Gordon, A.., Mirand, E. A., Wenig, J., Katz, R., and Zanjani, E. D.: Androgen actions on erythropoiesis. Ann. N.Y. Acad. ci. 149:318, Abexanian, R.: Urinary excretion of erythropoietin in normal men and women. Blood 28:344, Van Dyke, D., Nohr, M. L., and Lawrence, J. H.: Erythropoietin in the urine of normal and erythropoieticably abnormal human beings. Blood 28:535, Adamson, J. W., and Finch, C. A.: Erythropoietin and the pobycythemias. Ann. N.Y. Acad. ci. 149:56, Jepson, J. H., and McGarry, E. E.: Effect of growth hormone and other hormones on erythropoiesis and erythropoietin excretion of pituitary dwarfs. Ann. Intern. Med. 68:1169, 1968 (Abstract). 21. Jepson, J. H., McGarry, E. E., and Lowenstein, L.: Erythropoietin excretion in a hypopituitary patient. Arch. Intern. Med. 122:265, Fried, W., and Gurney, C. \V.: The erythropoietin response to testosterone in male and female mice. J. Lab. Clin. Med. 67:42, Fried, W., DeGowin, R., and Gurney, C. W.: Erythropoietin effect of testosterone in polycythemic mouse. Proc. oc. Exp. Biol. Med. 117:839, Gardner, F. H., and Pringle, J. C.: Androgens and erythropoiesis. Arch. Intern. Med. 17:112, Fried, W., Rishpon-Meyerstein, N., and Gurney, C. W.: The effect of testosterone on erythropoiesis of WW mice. J. Lab. Clin. Med. 7:813, 1967.
10 From by guest on January 22, 219. For personal use only : Erythropoietin and Erythropoiesis in Anemic Man Following Androgens RAYMOND ALEXANIAN Updated information and services can be found at: Articles on similar topics can be found in the following Blood collections Information about reproducing this article in parts or in its entirety may be found online at: Information about ordering reprints may be found online at: Information about subscriptions and AH membership may be found online at: Blood (print IN , online IN ), is published weekly by the American ociety of Hematology, 221 L t, NW, uite 9, Washington DC 236. Copyright 211 by The American ociety of Hematology; all rights reserved.
Antiduretic Hormone, Growth. Hormone & Anabolic Steroids
Goudarz Sadeghi, DVM, PhD, DSc Associate Professor of Pharmacology University of Tehran Faculty of Veterinary Medicine Veterinary Pharmacology Endocrine System Antiduretic Hormone, Growth Hormone & Anabolic
More informationAndrogens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent
Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred
More informationIssues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options
Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Androgens and Anabolic Steroids Page 1 of 57 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior
More informationNew Directions in Aplastic Anemia: What is on the Horizon
Case Presentation #1 New Directions in Aplastic Anemia: What is on the Horizon Gabrielle Meyers, MD 62 y/o male, with hypertension, who presented to his PCP for evaluation of fatigue, shortness of breath
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationDEPO-Testosterone Injection is available in two strengths, 100 mg/ml and 200 mg/ml testosterone cypionate.
Depo -Testosterone testosterone cypionate injection, USP CIII DESCRIPTION DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate
More informationAndrogenes and Antiandrogenes
Androgenes and Antiandrogenes Androgens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone [tess-toss-terone], the most important
More informationCreatine Versus Anabolic Steroids. Over the past few years, many athletes have been using performance-enhancing
Hester 1 Kyle Hester Instructor s Name ENGL 1013 Date Creatine Versus Anabolic Steroids Over the past few years, many athletes have been using performance-enhancing supplements on a regular basis. Two
More informationAffirming Care of the Transgender Patient
Mountain West AIDS Education and Training Center Affirming Care of the Transgender Patient Jessica Rongitsch, MD, FACP This presentation is intended for educational use only, and does not in any way constitute
More informationAdverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function
Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Associate Professor Caroline Kistorp, Ph.D Department of Internal Medicine, Herlev
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Androgens and Anabolic Steroids Page 1 of 53 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior
More informationSecrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin
+ Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Myodine 25 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Nandrodine laurate 25
More informationPRODUCT INFORMATION PROVIRON
PRODUCT INFORMATION PROVIRON NAME OF TE MEDICINE Mesterolone is a white to yellowish crystalline powder and is practically insoluble in water. The chemical name for mesterolone is 17 beta-ydroxy-1 alpha-methyl-5
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,
More informationEnhanced Linear Growth Responses in Hypopituitary Dwarfs Treated with Growth Hormone Plus Androgen versus Growth Hormone Alone
Pediat. Res. 8: 103-108 (1974) Androgen growth hormone fluoxymesterone hypopituitary dwarfs Enhanced Linear Growth Responses in Hypopituitary Dwarfs Treated with Growth Hormone Plus Androgen versus Growth
More informationRelationship between Aerobic Training and Testosterone Levels in Male Athletes
Relationship between Aerobic Training and Testosterone Levels in Male Athletes Siu Yuen Ng Biology 493 13 th December, 2010 Abstract Salivary testosterone levels of 11 athletes and 15 non athletes were
More informationTestosterone Topical/Buccal/Nasal
BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO
More informationIntroduction to the Doping Problem
Introduction to the Doping Problem Jordi Segura Director, WADA Accredited Antidoping Laboratory, IMIM-Hospital del Mar, Barcelona, Spain Doping and Society: towards the perfect human machine? ESOF, Barcelona
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through
More informationPsychology. Psychology & Performance Enhancing Substances. The Ideal Performance State. Relationship Between Confidence and Athletic Performance
Psychology & Performance Enhancing Substances Psychology The Ideal Performance State Absence of fear no fear of failure No thinking about or analysis of performance Narrow focus of attention concentrated
More informationInappropriate Testosterone Billings
Inappropriate Testosterone Billings Carla Patrick-Fagan March 30, 2015 Truven Health Analytics Inc. All Rights Reserved. 1 Agenda Proposed in the 2015 analytic plan Steroid prescriptions Code of Federal
More informationMonitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc.
Mr Mark Newman Monitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc. 2 Avoiding Pitfalls in (B)HRT Monitoring and Picking the Right Lab Test Objectives: Outline how expected
More informationReproductive DHT Analyte Information
Reproductive DHT Analyte Information - 1 - DHT Introduction Dihydrotestosterone (DHT) together with other important steroid hormones such as testosterone, androstenedione (ASD) and dehydroepiandrosterone
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationUpdates on Anti-doping and TUE Management in Paralympic Sport
International Paralympic Committee Updates on Anti-doping and TUE Management in Paralympic Sport Matthew Fedoruk, Ph.D. March 15, 2018 PyeongChang 2018 IPC Medical / Sports Science Committee Workshops
More informationIcd-10 low levels of testosterone
Icd-10 low levels of testosterone The Borg System is 100 % Icd-10 low levels of testosterone 1-10-2017 if your hormone levels are too high or too low, you may have a hormone disorder. Hormone diseases
More informationCLINICAL PHARMACOLOGY
TESTOPEL- testosterone pellet Slate Pharma ---------- DESCRIPTION TESTOPEL Pellets (testosterone) are cylindrically shaped pellets 3.2mm (1/8 inch) in diameter and approximately 9mm in length. Each sterile
More informationMIE KAMIYA Laboratory of Physiology, Ocean Research Institute, University of Tokyo, Nakano, Tokyo
Endocrinol. Japon. 1972, 19 (5), 489 `493 NOTE Hormonal Effect on Na-K-ATPase Activity in the Gill of Japanese Eel, Anguilla Japonica, with Special Reference to Seawater Adaptation MIE KAMIYA Laboratory
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through
More informationPHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor
PHYSICIANS CIRCULAR FINASTERIDE PROSCAR Tablet 5-Alpha Reductase Inhibitor FINASTERIDE (PROSCAR) a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme
More informationEstudos.
Estudos http://aformulabr.com.br/qrcode/oximetolonaafv01.pdf OXIMETOLONA Estimulador da hematopoese na anemia aplástica DESCRIÇÃO Oximetolona (17β-hidroxi-2-hidroximetileno-17α-metil-3-androstanona) é
More informationTransgender 201: Case Discussion Group
Transgender 201: Case Discussion Group Melissa Davis, MD Maria Barnett, DO October 19, 2017 Maria Barnett, DO, Date Welcome! Disclosures Introductions Discussion The total time of this workshop will depend
More informationDoping in Sports: Catching and Preventing It An Expert Interview With Gary I. Wadler, MD
Doping in Sports: Catching and Preventing It An Expert Interview With Gary I. Wadler, MD Carol Peckham; Gary I. Wadler, MD As part of our coverage of the 2012 Olympics, Medscape interviewed Gary I. Wadler,
More informationFemale testosterone level chart
Female testosterone level chart The Borg System is 100 % Female testosterone level chart Mar 23, 2015. Male, Female. Age: T Level (ng/dl):, Age: T Level (ng/dl):. 0-5 mo. 75-400, 0-5 mo. 20-80. 6 mos.-9
More informationFINCAR Tablets (Finasteride)
Published on: 10 Jul 2014 FINCAR Tablets (Finasteride) Composition FINCAR Tablets Each film-coated tablet contains: Finasteride USP - 5 mg Dosage Form Tablet Pharmacology Pharmacodynamics Mechanism of
More informationDrug Class Monograph
Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.291 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationHGH for Sale Natural Anti-Aging Human Growth Hormone
HGH for Sale Natural Anti-Aging Human Growth Hormone Human growth hormone is one of the hottest supplement trends on the market, and now you can purchase top-quality HGH to be delivered right to your home!
More informationQuestions for the Expert panel
Questions for the Expert panel A. analytical and peri-analytical aspects (complete: instrument reports, storage temperature, QC, etc.) can the abnormal result be explained by the analytical or pre-analytical
More informationUse of Performance Enhancing Substances Good Chemistry Gone Bad. Evan M. Klass, M.D., F.A.C.P.
Use of Performance Enhancing Substances 2017 Good Chemistry Gone Bad Evan M. Klass, M.D., F.A.C.P. Doping the use of banned athletic performance-enhancing drugs by competitors Performance enhancing substances
More informationLIFETIME FITNESS HEALTHY NUTRITION. UNIT 2 Lesson 14 FLEXIBILITY LEAN BODY COMPOSITION
LIFETIME FITNESS HEALTHY NUTRITION MUSCULAR STRENGTH AEROBIC ENDURANCE UNIT 2 Lesson 14 FLEXIBILITY LEAN BODY COMPOSITION MUSCULAR ENDURANCE Created by Derek G. Becher B.P.E., B. Ed., AFLCA Resistance
More informationAnabolic Androgenic Steroids
Anabolic Androgenic Steroids 1 / 6 2 / 6 3 / 6 Anabolic Androgenic Steroids What are anabolic steroids? Anabolic steroids are synthetic, or human-made, variations of the male sex hormone testosterone.
More informationPackage Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)
Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains
More informationIcd 10 hormone replacement therapy male
Icd 10 hormone replacement therapy male 2018 ICD - 10 code for Hormone replacement therapy is Z79.890. Lookup the complete ICD 10 Code details for Z79.890. The ICD - 10 system requires that. TEENren who
More informationCinryze. Cinryze (C1 esterase inhibitor [human]) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.05 Subject: Cinryze Page: 1 of 5 Last Review Date: September 20, 2018 Cinryze Description Cinryze
More informationFair Competition and Drug Control
Fair Competition and Drug Control Speaker: Dr. Yves Bonnaire General Manager, Laboratoire des Course Hippiques Dr Yves BONNAIRE Advisory Council LOGO PROHIBITED SUBSTANCES an update. PROHIBITED SUBSTANCES
More informationWADA Technical Document TD2014EAAS. Endogenous Anabolic Androgenic Steroids Measurement and Reporting
Endogenous Anabolic Androgenic Steroids Measurement and Reporting 1.0 Introduction The purpose of this Technical is to harmonize the approaches to the measurement and reporting of endogenous anabolic androgenic
More informationTestosterone Use and Effects
Parkland College Natural Sciences Poster Sessions Student Works 2013 Testosterone Use and Effects Brandon Mills Parkland College Recommended Citation Mills, Brandon, "Testosterone Use and Effects" (2013).
More informationMI Androgen Deficiency Hypogonadism
MI Androgen Deficiency Hypogonadism WADA TUE Expert Group John A Lombardo, MD October 2014, Columbus, Ohio USA Hypothalamic-Pituitary-Gonadal Axis / 2 Hypogonadism/Androgen Deficiency Clinical syndrome:
More informationShort- and Long-Term Effects of Estrogen and Synthetic Anabolic Hormone in Postmenopausal Osteoporosis
Short- and Long-Term Effects of Estrogen and Synthetic Anabolic Hormone in Postmenopausal Osteoporosis B. LAWRENCE RIGGS, JENIFER JOWSEY, RALPH S. GOLDSMITH, PATRICK J. KELLY, DAVID L. HOFFMAN, and CLAUDE
More informationNational Institute for Public Health and the Environment Annual CRL workshop 22 October Update on natural Hormone studies
2008 Annual CRL workshop 22 October 2008 Update on natural Hormone studies Natural hormone studies: update Possible approaches - C12/C13 ratio: can result in proof of abuse - Determination of intact esters
More informationSue Marty, Ph.D., D.A.B.T. The Dow Chemical Company TERA Endocrine Workshop April 23, 2013
Sue Marty, Ph.D., D.A.B.T. The Dow Chemical Company TERA Endocrine Workshop April 23, 2013 Agenda Value of WoE/MoA determinations in EDSP Information used to examine potential endocrine activity and/or
More informationPerformance Profiling: A Role for Sport Science in the Fight Against Doping?
TECHNICAL REPORT International Journal of Sports Physiology and Performance, 2009, 4, 129-133 2009 Human Kinetics, Inc. Performance Profiling: A Role for Sport Science in the Fight Against Doping? Yorck
More informationProviron. Proviron Functions & Traits: (Mesterolone)
Proviron (Mesterolone) Proviron represents one of the oldest anabolic androgenic steroids on the market. A product of the giant pharmaceutical company Schering, it would first appear in 1934. Officially
More informationRobert Perlstein, M.D. Medical Officer. Center for Drug Evaluation and Research. U.S. Food & Drug Administration
-------------------- Robert Perlstein, M.D. Medical Officer Center for Drug Evaluation and Research U.S. Food & Drug Administration -------------------- Sentencing of Food and Drug Offenses Before the
More informationAre Steroids Worth the Risk?
Are Steroids Worth the Risk? Dominic has baseball on the brain. Just being good isn't enough he wants to be the best. He dreams of playing in the majors someday, but worries about the intense competition
More informationTESTOFEN. Anabolic & Androgenic Activity GENCOR PACIFIC, INC. Fenugreek Extract standardized for FENUSIDE TM. Copyright 2005 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920E. Orangethorpe Avenue, Suite B, Anaheim, CA. 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com manu@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationFollowing an Olympics shadowed by the Russian
CEUQuiz Performance Enhancing Drugs Scandals, Oversite and Advancement Following an Olympics shadowed by the Russian performance enhancing drug (PED) scandal, banned substances once again reach the forefront
More informationDonald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone
Focus on CME at University of Alberta ADAM: Dealing with the Decline Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May 2005 We now know there is a decline in total
More informationPRODUCT INFORMATION. Testosterone Phenylpropionate: Testosterone Phenylpropionate is 3-oxoandrost-4-en-17β-yl
PRODUCT INFORMATION SUSTANON '250' NAME OF THE MEDICINE Sustanon '250' ('250' mg/ml for injection): testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, testosterone decanoate.
More informationTestosterone Effects in Transmen
Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal
More informationThe Anabolic Steroid, Stanozolol
THERAPEUTIC TRIALS The Anabolic Steroid, Stanozolol Its Evaluation in Debilitated Children C. H. CARTER, M.D. As ~ ils testosterone and its derivatives came to be used for their androgenic effect, and
More informationFigure 2. RESULTS DATA ANALYSIS
ANDROGEN PARAMETERS IN HIRSUTE AND NORMAL FEMALE PATIENTS: IS THERE A ROLE FOR THE FREE ANDROGEN INDEX (FAI)? Castracane VD 1, Childress E 1, Tawwater B 1, Vankrieken L 2, El Shami AS 2 ( 1 Department
More informationPublic Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended
Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Andriol Testocaps, Sustanon and Testosterone Implants [] NL/W/0026/pdWS/001
More informationCREATINE AND GUANIDOACETIC ACID
J. clin. Path. (1950), 3, 345. CREATINE AND GUANIDOACETIC ACID METABOLISM IN PITUITARY DISEASE J. N. CUMINGS From the Clinical Pathological Laboratory, National Hospital, BY (RECEIVED FOR PUBLICATION APRIL
More informationWhat do these athletes have in common?
What do these athletes have in common? Drugs in Sport Why do athletes cheat? 1988 Olympics 100m Final Why is this photo so iconic? 1988 Olympics 100m Final First time ever 4 of the 8 finalists run under
More informationTESTOVIRON 300 TESTOCYP 200 INJECTABLE PRODUCTS
Platinum Biotech has a commitment to all people, a commitment of improving the quality of life for each and every person worldwide, through which we constantly strive to innovate, improve and increase
More informationLearning Goals. What are steroids? Who uses steroids? Why do people use steroids? What are the health risks associated with using steroids?
Learning Goals What are steroids? Who uses steroids? Why do people use steroids? What are the health risks associated with using steroids? Performance Enhancing Drugs Nutritional Aids Pharmacological Aids
More informationTREATMENT OPTIONS FOR MALE HYPOGONADISM
TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,
More informationTalent. Motivation Training. What makes a great athlete? Data from elite athletes. Trainability Avoiding injury. In other words...
08/09/2017 Making decisions about supplement use Ron Maughan St Andrews University Scotland Seminar Targalt toidulisanditest IOC Conference on Dietary Supplements and the Elite Athlete 31. augustil kell
More informationOriginal Research Declining testicular function in aging men
(2003) 15, Suppl 4, S3 S8 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Original Research 1 * 1 Wesley Woods Health Center, Atlanta, Georgia, USA Age-related
More informationXYOSTED (testosterone enanthate) injection, for subcutaneous use CIII Initial US approval: 1953 IMPORTANT SAFETY INFORMATION
ANTARES PHARMA ANNOUNCES THE COMMERCIAL AVAILABILITY OF XYOSTED (TESTOSTERONE ENANTHATE) INJECTION A NEW TREATMENT FOR ADULT MEN DIAGNOSED WITH TESTOSTERONE DEFICIENCY XYOSTED - A Novel Subcutaneous Testosterone
More informationThe Testosterone Quandary. Beth Crowder, PhD, APRN
The Testosterone Quandary Beth Crowder, PhD, APRN Objectives Define testosterone, the hypothalamic-pituitary-gonadotrophic axis, and normal blood levels List functions of testosterone and symptoms of low
More information17-KETOSTEROIDS DURING THE MENSTRUAL
J. clin. Path. (1951). 4, 78. THE EXCRETION OF PREGNANEDIOL AND 17-KETOSTEROIDS DURING THE MENSTRUAL CYCLE IN BENIGN HIRSUTISM BY From the Department of Clinical Pathology, Guy's Hospital, London (RECEIVED
More informationAll About T Testosterone for FTMs. Presented by John Otto, MLIS
All About T Testosterone for FTMs Presented by John Otto, MLIS Who? Anyone thinking about transitioning Those who have transitioned, but want to know more Empowerment from self-managing transition Allies
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAndroGel. (testosterone gel) 1% H 3 C
1 AndroGel (testosterone gel) 1% 500122/500127 Rev Dec 2004 DESCRIPTION AndroGel (testosterone gel) is a clear, colorless hydroalcoholic gel containing 1% testosterone. AndroGel provides continuous transdermal
More informationture of the creatinuria of patients with diseases of the thyroid. Blood serum and urine were analyzed for creatinine and
THE MODE OF EXCRETION OF CREATINE AND CREATINE METABOLISM IN THYROID DISEASE1 By NICHOLAS A. TIERNEY AND JOHN P. PETERS (From the Department of Internal Medicine, Yale University School of Medicine, and
More informationEssential Standards. 8.ATOD.2 Understand the health risks associated with alcohol, tobacco, and other drug use.
Essential Standards 8.ATOD.2 Understand the health risks associated with alcohol, tobacco, and other drug use. Clarifying Objective 8.ATOD.2.2 Evaluate the magnitude and likelihood of the risks associated
More informationCreatine. Travis Harvey, PhD, CSCS
Creatine Travis Harvey, PhD, CSCS Overview This is not exhaustive it s applicable Disclaimer BLUF Myths Legends Protective effects Move, Shoot, Communicate Bottom Line Collectively, results from these
More informationWHY IS PREVENTION IMPORTANT?
A GUIDE TO TRUST THE POWER OF PREVENTION < 2 > WHY IS PREVENTION IMPORTANT? Hereditary angioedema (HAE) symptoms can range in severity. Some attacks may be mild or temporarily disabling, but others can
More informationCHAPTER XVI PDL 101 HUMAN ANATOMY & PHYSIOLOGY. Ms. K. GOWRI. M.Pharm., Lecturer.
CHAPTER XVI PDL 101 HUMAN ANATOMY & PHYSIOLOGY Ms. K. GOWRI. M.Pharm., Lecturer. Muscle Cell Metabolism Muscle Cells Provide ATP to Drive the Crossbridge Cycle The sources of ATP: Available ATP in the
More informationDevelopment of a Clinical Research Method for the Measurement of Testosterone. Dihydrotestosterone
Development of a Clinical Research Method for the Measurement of Testosterone and Dihydrotestosterone Martijn van Faassen, Maarten van den Noort and Ido Kima University Medical Center, Groningen, Netherlands
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery
Pros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery David T Zava, PhD ZRT laboratory A Guide to Steroid Hormone Testing in Different Body Fluids Following
More informationNatural estrogens estradiol estrone estriol
Estrogens Natural estrogens estradiol estrone estriol Nonsteroidal synthetic Diethylstilbestrol Chlorotrianisene Methallenestril Steroidal synthetic Ethinyl estradiol Mestranol Quinestrol To decrease some
More informationAuthor of: The Six-Pack Diet Plan: The Secrets to Getting Lean Abs and a Rock-Hard Body Permanently
Interview with Rehan Jalali, President, Supplement Research Foundation Author of: The Six-Pack Diet Plan: The Secrets to Getting Lean Abs and a Rock-Hard Body Permanently Background Information: According
More informationGynaecomastia. Benign breast conditions information provided by Breast Cancer Care
Gynaecomastia This booklet tells you about gynaecomastia. It explains what gynaecomastia is, what causes it, how it s diagnosed and what will happen if it needs to be treated or followed up. Benign breast
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThe ICL Insider. Lab Testing: Testosterone. In This Issue. The Debate
The ICL Insider February 2017 Volume 2, Issue 2 Lab Testing: Testosterone In This Issue Testosterone shashtilak@iclabs.ca Next Issue: Expected Release April 2017 The Debate Aging is accompanied by various
More information4.2 Posology, method and duration of administration
The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it in May 2011. 1. NAME OF MEDICINAL PRODUCT Testoviron Depot Oily solution for injection
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH) and prostatic
More informationHAIR LOSS HORMONE IMBALANCE HAIR LOSS HORMONE IMBALANCE PDF HAIR LOSS - WIKIPEDIA HORMONE IMBALANCE CHECKLIST - WEIGHT LOSS PROGRAMS
PDF HAIR LOSS - WIKIPEDIA HORMONE IMBALANCE CHECKLIST - WEIGHT LOSS PROGRAMS 1 / 6 2 / 6 3 / 6 hair loss hormone imbalance pdf Male pattern hair loss is believed to be due to a combination of genetics
More informationHyperbarics and Wound Care: A Perfect Partnership
Hyperbarics and Wound Care: A Perfect Partnership Juan O Bravo MD CWSP UHM Medical Director Center for Wound Care and Hyperbaric Medicine at Broward Health Coral Springs Disclosures I am part of the advisory
More information